MDT生命科学与高端医疗● Live Quotes Active

Medtronic plc.

No mega hedge funds in our coverage currently report a major 13F position in this stock

Live Price
24h Change
Mega Funds Holding
0/ 33 funds

Coverage: 0.0%

Avg Portfolio Weight
0%

-

Wall St Sentiment
0%Bullish
+0/0/-0
Total Tracked Shares
0shares

Based on SEC 13F filings

SGDC Dual-Core EngineSuper-Growth Dual-Core Radar

🚀MDT SGDC Quant Rating & Setup

Open SGDC Screener↗
4P Grade
C 级(66分)
RS Rating
38/ 99
Pattern Setup
Extended
Pivot Benchmark
$93.93Support: $89.23

📌 Business Moat Summary:Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

ℹ️
13F Hedge Fund Coverage NoticeNone of the 33 tracked mega hedge funds (e.g., Berkshire Hathaway, Bridgewater, Renaissance, Citadel) currently report a major 13F position in MDT.✦ Note: This stock is actively tracked by the SGDC Super-Growth Quant Engine (4P Grade C, RS Rating 38).

📈8-Quarter Institutional Ownership Evolution

Historical trajectory of institutional holders and allocation weight across the last 8 quarters

Select Quarter:
0% 均仓
0 f2026 Q2
0% 均仓
0 f2026 Q1
0% 均仓
0 f2025 Q4
0% 均仓
0 f2025 Q3
0% 均仓
0 f2025 Q2
0% 均仓
0 f2025 Q1
0% 均仓
0 f2024 Q4
0% 均仓
0 f2024 Q3
2026 Q2|Report Date: 2026-06-30
Holding Funds: 0 家Total Shares: 0Avg Weight: 0%

🏛️Institutional Investors Holding this Stock

Examine each hedge fund holding this ticker, weight, shares, and recent action

Sort by:
Manager / FundFund AUMWeightShares HeldActionAction
No tracked mega hedge funds currently hold this stock.
🎯

Want to see Wall Street's Top 50 Consensus Buys?

Instead of checking individual stocks, get the complete list of high-conviction overlap picks across 33 hedge funds.

Go to Consensus Screener →

⚡Planning to trade MDT?

Add this symbol to your private journal or dividend tracker to monitor institutional moves.

MDT (Medtronic plc.) Institutional 13F Ownership & SGDC Growth Analysis 2026 | WhaleTracker